Press release
Mesothelioma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Mesothelioma treatment.
• The leading companies working in the Mesothelioma Market include Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Promising Mesothelioma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
• April 2024: CRISPR Therapeutics AG announced a study of Phase 1 & 2 clinical trials for CTX131. This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
• April 2024: A2 Bio therapeutics Inc. announced a study of Phase 1 & 2 clinical trials for A2B694. The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express MSLN and have lost HLA-A*02 expression.
Request a sample and discover the recent advances in Mesothelioma Treatment Drugs @ Mesothelioma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Mesothelioma Overview
Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 - 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue. Any amount of asbestos exposure can cause mesothelioma. However, certain occupations may experience higher rates of exposure. There are four main types of mesothelioma based on tumor location. The most common type is malignant pleural mesothelioma. The pattern of nodal metastases is different from that seen in lung cancer. With malignant pleural mesothelioma, there is a direct local invasion of the lymph nodes. Overall, the involvement of lymph nodes in malignant pleural mesothelioma is not common.
Find out more about Mesothelioma Therapeutics Assessment @ Mesothelioma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Mesothelioma Emerging Drugs Profile
• TR002: Trizell
TR002 (nadofaragene firadenovec) is an investigational gene therapy consisting of an adenovirus containing the gene interferon alfa-2b. It is administered by catheter into the pleural cavity, where the virus enters the cells lining the pleural cavity. Inside the cells, the virus breaks down leaving the active gene to do its work. The internal gene/DNA machinery of the cells picks up the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach turns the patient's own pleural cavity cells into multiple interferon microfactories, enhancing the body's natural defences against the cancer.
• MTG201: Momotaro-Gene
MTG201 is a novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company's proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, increased expression of REIC/Dkk-3 gene in normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune suppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well positioned to work synergistically with checkpoint inhibitors such as nivolumab.
• PM8002: Biotheus
PM8002 is a bispecific antibody targeting both PD-L1 and VEGF-A. PD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and enhance cancer growth and metastasis. In the clinical trial study PM8002 showed encouraging antitumor activity and good safety in patients with advanced solid tumors. Currently, the drug is in the Phase II stage of its development for the treatment of Mesothelioma.
• MT-8421: Molecular Templates
MT-8421, along with MT-6402 (PD-L1 Targeting ETB with Antigen Seeding Technology), represents our unique approach to immuno-oncology based on dismantling the TME through direct cell-kill of tumor and immune cells and not only the blocking of ligand-ligand interactions seen with current antibody therapeutics. The ETB approach includes potent destruction of CTLA4+ regulatory T cells ("Tregs") via enzymatic ribosome destruction, and the mechanism of cell kill is independent of TME. MT-8421 preferentially destroys high CTLA4 expressing Tregs in the TME relative to peripheral Tregs which are lower CTLA4 expressing. Currently, the drug is in the Phase I stage of its development for the treatment of Mesothelioma.
Mesothelioma Pipeline Therapeutics Assessment
There are approx. 50+ key Mesothelioma companies which are developing the Mesothelioma therapies. The Mesothelioma companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
DelveInsight's Mesothelioma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Mesothelioma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Learn more about the emerging Mesothelioma Pipeline Therapies @ Mesothelioma Clinical Trials Assessment
Scope of the Mesothelioma Pipeline Report
• Coverage- Global
• Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Mesothelioma Companies- Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.
• Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.
Dive deep into rich insights for new drugs for Mesothelioma Treatment, Visit @ Mesothelioma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Mesothelioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mesothelioma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Mesothelioma Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TRC102: TRACON Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SG001: CSPC ZhongQi Pharmaceutical Technology
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Mesothelioma Key Companies
23. Mesothelioma Key Products
24. Mesothelioma- Unmet Needs
25. Mesothelioma- Market Drivers and Barriers
26. Mesothelioma- Future Perspectives and Conclusion
27. Mesothelioma Analyst Views
28. Mesothelioma Key Companies
29. Appendix
For further information on the Mesothelioma Pipeline therapeutics, reach out to Mesothelioma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mesothelioma Pipeline Outlook Report 2024 (Updated) here
News-ID: 3460530 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Mesothelioma
Mesothelioma Resource Centre Introduced the All Legal Rights and Options Platfor …
Mesothelioma Resource Centre announced the platform for all legal rights and options of Asbestos & Mesothelioma. It is the legal and health resources center for all sufferers of mesothelioma cancer, a cancer almost always caused by exposure to asbestos.
Generally, a mesothelioma victim must immediately seek redress once diagnosed with the cancer because if the disease has been established to be work-related and the responsible company is identified, a mesothelioma…
New Mesothelioma Treatment Technique Developed
Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School.
The surgical technique was applied on a mesothelioma patient…
Mesothelioma Cancer: Possible Treatment Option
An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose.
The use of a genetically engineered virus to disrupt the function…
Veteran Passed Away from Mesothelioma Cancer
It has been reported that a U.S. Army veteran passed away at the age of 64 from the asbestos cancer, malignant mesothelioma. He retired from the U.S. Army Corps of Engineers after 25 years of service. Prior to his military career, he worked at a steel company. It is likely that his mesothelioma was caused by asbestos exposure that he encountered at the steel company and during military service.
Malignant mesothelioma…
Weitz & Luxenberg Mesothelioma Lawyers win $1.28 Million Settlement in Mesotheli …
Weitz & Luxenberg mesothelioma lawyers recently secured a $1.28 million settlement for a 77-year-old former carpenter suffering from the asbestos cancer, mesothelioma. Prior to this settlement, Weitz & Luxenberg obtained $842,000 from another defendant.
The former carpenter is the father of six children and devoted his 30-year career to beautifying such New York City landmarks as Yankee Stadium and the Empire State Building. He was diagnosed with mesothelioma in…
For Mesothelioma Victims, Knowledge is Power
For people with malignant mesothelioma, a rare and serious cancer caused by asbestos, finding information on their illness can be as challenging as its symptoms. The Law Offices of James Sokolove (www.jimsokolove.com) hopes to change this with the launch of the Mesothelioma Resource Center, a comprehensive online resource designed for mesothelioma victims as well as their caregivers and families.
“So many of these individuals already feel alone in their struggle,”…